# Deep Verify V7.7 - Verification Report

**Artifact:** Medical Diagnostic Decision Support System (DxAssist) Technical Specification v1.0
**Path:** C:\Users\lukasz.krysik\Desktop\BMAD-MY-REPO\BMAD-METHOD\src\testing\results\experiments\artifacts\artifact-t22.md
**Date:** 2026-01-19
**Workflow Version:** V7.7

---

# PHASE 0: ARTIFACT ANALYSIS

## 0.1 Self-Check

Three ways I could deceive myself with THIS artifact:

1. **Accepting medical AI claims at face value** - I might trust that stated accuracy metrics (99.9% sensitivity/specificity) are achievable because they sound professional and are presented with technical detail.
   - Prevention strategy: Actively challenge whether these numbers are realistic against known medical diagnostic benchmarks and statistical limits.

2. **Conflating "sounds regulatory compliant" with "is regulatory compliant"** - The document mentions FDA Class III, HIPAA, ISO standards extensively, which might lead me to assume actual compliance rather than just stated intent.
   - Prevention strategy: Distinguish between "we will comply" and "we have evidence of compliance" - look for actual validation data.

3. **Accepting the continuous learning + deterministic output combination as coherent** - These may be contradictory requirements that I might gloss over because each sounds reasonable individually.
   - Prevention strategy: Explicitly check for logical compatibility between stated requirements.

My limitations for this artifact:
- I cannot empirically verify if 99.9% accuracy is achievable for rare disease diagnosis
- I cannot validate whether the FDA approval strategy is actually viable
- I cannot determine if the technical architecture would actually meet performance claims
- I lack access to real-world benchmarks for medical AI diagnostic systems
- I cannot verify if 10,000+ conditions can be supported with stated accuracy

---

## 0.2 Element Extraction

### 0.2.1 Claims

| ID | Claim | Type | Location | Red Flag? |
|----|-------|------|----------|-----------|
| C1 | "achieving 99.9% sensitivity and 99.9% specificity" | PERFORMANCE | Section 1.1 | YES - Exceptional accuracy without methodology |
| C2 | "10,000+ disease conditions supported" | PERFORMANCE | Section 1.2 | YES - Large number without data source |
| C3 | "Real-time diagnosis in <5 seconds" | PERFORMANCE | Section 1.2 | MAYBE - needs validation |
| C4 | "Offline capability for rural clinics" | FACTUAL | Section 1.2 | NO |
| C5 | "99.99% uptime" | PERFORMANCE | Section 1.3 | YES - Very high SLA claim |
| C6 | "Deterministic output for reproducibility" | GUARANTEE | Section 2.2.2 | YES - Combined with continuous learning |
| C7 | "7 independent models vote on each diagnosis" | FACTUAL | Section 3.2 | NO |
| C8 | "Continuous calibration: Model outputs calibrated against outcomes" | FACTUAL | Section 3.2 | NO |
| C9 | "same symptoms = same diagnosis" | GUARANTEE | Section 3.3 | YES - Contradicts continuous learning |
| C10 | "Incremental model update with new cases" | FACTUAL | Section 4.1 | NO |
| C11 | "FDA Notification: Report significant model changes to FDA" | FACTUAL | Section 4.2 | NO |
| C12 | "Generation time: <500ms" | PERFORMANCE | Section 5.2 | NO - within budget |
| C13 | "Training Data: 50M de-identified patient records" | FACTUAL | Section 13.1 | MAYBE - source unclear |
| C14 | "Validation: 10M held-out records" | FACTUAL | Section 13.1 | MAYBE - source unclear |
| C15 | "DxAssist is classified as FDA Class III medical device requiring Pre-Market Approval" | FACTUAL | Section 6.1 | NO |
| C16 | "Human-in-Loop Fallback: Edge cases escalated to physician" | FACTUAL | Section 3.2 | NO |
| C17 | "500MB footprint" for offline model | PERFORMANCE | Section 8.1 | MAYBE - for 5000 conditions |
| C18 | "Top 5000 conditions" in offline mode | PERFORMANCE | Section 8.1 | NO |
| C19 | "PPV/NPV: Varies by disease prevalence (disclosed per condition)" | FACTUAL | Section 10.2 | NO |
| C20 | "Total response time: 4600ms actual vs 5000ms target" | PERFORMANCE | Section 9.1 | NO - provides breakdown |
| C21 | "Single instance: 50 diagnoses/minute" | PERFORMANCE | Section 9.2 | NO |
| C22 | "Physicians using DxAssist maintain their standard malpractice coverage" | FACTUAL | Section 10.3 | YES - legal claim without basis |
| C23 | "System's recommendations do not create additional liability exposure" | GUARANTEE | Section 10.3 | YES - legal guarantee |
| C24 | "Retrospective study on 100K cases" for clinical validation | FACTUAL | Section 6.2 | NO |
| C25 | "Performance on extremely rare conditions (<1:1,000,000) may be limited" | CONDITIONAL | Section 12.2 | NO - honest limitation |

### 0.2.2 Terms

| Term | Defined? | Definition/Usage | Potential problem |
|------|----------|------------------|-------------------|
| Sensitivity | IMPLICIT | 99.9% - medical definition assumed | Assumes reader knows medical stats |
| Specificity | IMPLICIT | 99.9% - medical definition assumed | Assumes reader knows medical stats |
| Rare diseases | NO | Not defined what "rare" means | Ambiguous scope |
| Deterministic | YES | "same symptoms = same diagnosis" | Conflicts with continuous learning |
| Continuous Learning | YES | "Incremental model update" | Conflicts with deterministic |
| FDA Class III | NO | Assumed known | Missing context on implications |
| HIPAA | NO | Assumed known | Missing scope definition |
| Bayesian networks | NO | Used in architecture | Technical term, no explanation |
| SHAP | NO | Used in explanation | Technical term, no definition |
| Ensemble | IMPLICIT | "7 independent models" | Partial definition |
| Edge cases | NO | "escalated to physician" | What defines an edge case? |
| Calibration | IMPLICIT | "calibrated against outcomes" | Partial definition |
| BioBERT | NO | Used for encoding | Technical term, no explanation |

### 0.2.3 Requirements

| ID | Requirement | Measurable? | Dependencies |
|----|-------------|-------------|--------------|
| R1 | 99.9% sensitivity | YES | Training data, model architecture |
| R2 | 99.9% specificity | YES | Training data, model architecture |
| R3 | <5 second response time | YES | Hardware, algorithm efficiency |
| R4 | 99.99% uptime | YES | Infrastructure, redundancy |
| R5 | 10,000+ conditions | YES | Knowledge base, training data |
| R6 | FDA Class III compliance | PARTIALLY | Regulatory approval process |
| R7 | HIPAA compliance | PARTIALLY | Data handling procedures |
| R8 | Offline capability | YES | Local model, storage |
| R9 | Deterministic outputs | YES | Algorithm design |
| R10 | Continuous learning | YES | Learning module design |
| R11 | Explainable outputs | PARTIALLY | Explanation quality subjective |
| R12 | EHR integration | YES | FHIR compliance |

### 0.2.4 Assumptions

| ID | Assumption | Explicit? | Impact if false |
|----|------------|-----------|-----------------|
| A1 | Patient data is accurate and complete | YES | Diagnosis accuracy drops significantly |
| A2 | EHR systems provide real-time data access | YES | Real-time capability fails |
| A3 | Physicians have appropriate training | YES | Misuse of system |
| A4 | Internet connectivity available for cloud mode | YES | Degrade to offline only |
| A5 | Sufficient historical data exists for all 10,000 conditions | YES | Cannot achieve stated accuracy for rare conditions |
| A6 | 50M de-identified patient records available | IMPLICIT | Training quality compromised |
| A7 | Regulatory approval achievable | IMPLICIT | Cannot deploy as Class III |
| A8 | Malpractice coverage unchanged with AI use | IMPLICIT | Legal liability issues |
| A9 | 99.9%/99.9% is achievable for 10,000 conditions | IMPLICIT | Core value proposition fails |
| A10 | Continuous learning compatible with FDA approval | IMPLICIT | Regulatory conflict |

---

## 0.3 Generated Checklist

### For Claims:
- [ ] C1: Is 99.9% sensitivity AND 99.9% specificity simultaneously achievable for 10,000 rare disease conditions?
- [ ] C2: Is supporting 10,000+ conditions with claimed accuracy realistic?
- [ ] C5: Is 99.99% uptime (52 min downtime/year) achievable for a medical system?
- [ ] C6: Can deterministic output coexist with continuous learning?
- [ ] C9: Does "same symptoms = same diagnosis" hold when model updates?
- [ ] C22: Is the malpractice claim legally accurate?
- [ ] C23: Is "no additional liability" a valid guarantee?

### For Terms:
- [ ] T1: Is "rare diseases" defined with clear prevalence threshold?
- [ ] T2: Is "deterministic" reconcilable with "continuous learning"?
- [ ] T3: Is "edge case" defined for escalation criteria?

### For Requirements:
- [ ] R1+R2: Are these requirements achievable together at claimed level?
- [ ] R5: What is the data source for 10,000 conditions?
- [ ] R9+R10: Are deterministic and continuous learning compatible?

### For Assumptions:
- [ ] A5: Does sufficient historical data exist for all 10,000 conditions, especially rare ones?
- [ ] A9: What evidence supports 99.9%/99.9% achievability?
- [ ] A10: Is continuous learning compatible with FDA Class III?

### Red Flags to investigate:
- [ ] 99.9%/99.9% accuracy - extraordinary claim needing extraordinary evidence
- [ ] Deterministic + Continuous Learning - logical contradiction
- [ ] Legal guarantees about malpractice - beyond technical scope
- [ ] 10,000 conditions with uniform high accuracy - statistical challenge

---

## 0.4 Method Selection

### Tier 1 (Universal) - ALWAYS:
- [x] M1 Consistency Check
- [x] M2 Completeness Check
- [x] M3 Scope Alignment

### Tier 2 (Claim-Level) - for each claim:
- [x] M4 Falsifiability Check (x25 claims)
- [x] M5 Evidence Demand (x25 claims)
- [x] M6 Critical Challenge (for red-flagged claims: C1, C2, C5, C6, C9, C22, C23)

### Tier 3 (Conditional):
- [x] M7 Pairwise Compatibility - 12 requirements present
- [x] M8 Vocabulary Consistency - technical terms present
- [x] M9 Theoretical Limits - GUARANTEE claims exist (C6, C9, C23)
- [x] M10 Dependency Analysis - dependencies identified

### Tier 4 (Domain-Specific):
- [ ] M11 Domain KB Available - No specific KB loaded
- [ ] M12 Technical Term Verifier - No KB definitions

---

## 0.5 Triage

| Metric | Value |
|--------|-------|
| Claims count | 25 |
| Red flags count | 7 |
| Requirements count | 12 |
| Assumptions count | 10 |
| Complexity estimate | HIGH |

**Estimated effort:** 15-20K tokens

---

# PHASE 1: TIER 1 VERIFICATION (Universal)

## M1: Consistency Check

**Status: FAIL**

| ID | Type | Element A | Element B | Inconsistency |
|----|------|-----------|-----------|---------------|
| I1 | LOGICAL | C6: "Deterministic output for reproducibility" | C10: "Incremental model update with new cases" | If model updates continuously, outputs cannot remain deterministic across time. Same input will yield different outputs after model update. |
| I2 | LOGICAL | C9: "same symptoms = same diagnosis" | Section 4.1: "retrain() Incremental model update" | After each retrain, the model changes, so same symptoms will NOT yield same diagnosis across model versions. |
| I3 | STRUCTURAL | R1+R2: 99.9% sensitivity AND specificity | R5: 10,000+ conditions | For rare diseases with limited training data, achieving 99.9% accuracy across ALL 10,000 conditions is statistically implausible. The requirement undermines itself. |
| I4 | SEMANTIC | "Rare diseases" (Section 1.1) | "Top 5000 conditions" offline (Section 8.1) | If rare diseases are the focus, how are 5000 "most common" conditions selected for offline use? The offline subset may not include the rare diseases the system is designed for. |
| I5 | LOGICAL | C16: "Edge cases escalated to physician" | C1: "99.9% sensitivity" | If cases are escalated, what counts as a "diagnosis"? The 99.9% might exclude escalated cases, making the metric misleading. |

---

## M2: Completeness Check

**Status: PARTIAL**

| ID | Gap type | Element | Impact |
|----|----------|---------|--------|
| G1 | MISSING_SECTION | Training data sources | Cannot validate data quality or bias |
| G2 | MISSING_SECTION | Failure mode analysis | Unknown system behavior at boundaries |
| G3 | MISSING_SECTION | Accuracy methodology | How was 99.9% measured? What test set? |
| G4 | MISSING_SECTION | Edge case definition | Unclear escalation criteria |
| G5 | MISSING_SECTION | Model update FDA pathway | How do updates get approved? |
| G6 | MISSING_SECTION | Demographic performance breakdown | Bias risk unaddressed in spec |
| G7 | PLACEHOLDER | "50M de-identified patient records" | No source or acquisition plan |
| G8 | MISSING_SECTION | Confidence threshold definitions | When is confidence "too low"? |
| G9 | MISSING_SECTION | Rollback criteria | When does performance monitoring trigger rollback? |
| G10 | MISSING_SECTION | Legal opinion on malpractice claims | Section 10.3 makes legal claims without legal basis |

---

## M3: Scope Alignment

**Declared goal:** "AI-powered diagnostic decision support system designed to help physicians diagnose rare diseases with exceptional accuracy while meeting all regulatory requirements"

| Goal element | Status | Where addressed | CUI BONO if omitted |
|--------------|--------|-----------------|---------------------|
| Help physicians diagnose | FULL | Sections 2, 3, 5 | N/A |
| Rare diseases focus | PARTIAL | Mentioned but undefined | AGENT - avoids hard definition |
| Exceptional accuracy | FULL | 99.9%/99.9% claimed | N/A |
| Meet regulatory requirements | PARTIAL | FDA/HIPAA mentioned, pathway unclear | AGENT - avoids compliance details |

**Scope creep:**
- Section 8 (Offline Operation) - Useful but expands scope significantly
- Section 10 (Liability Framework) - Makes legal claims outside technical specification scope
- Section 4 (Continuous Learning) - Creates complexity that conflicts with core requirements

---

# PHASE 2: TIER 2 VERIFICATION (Claim-Level)

## M4: Falsifiability Check (Selected Key Claims)

**Claim C1:** "achieving 99.9% sensitivity and 99.9% specificity"
- Falsifiable: YES
- Criterion: Test on independent dataset; if sensitivity or specificity falls below 99.9%, claim is false
- Testability: HARD - requires large, high-quality test set with ground truth diagnoses for 10,000 conditions

**Claim C2:** "10,000+ disease conditions supported"
- Falsifiable: YES
- Criterion: Enumerate conditions; if count < 10,000, claim is false
- Testability: EASY - list the conditions

**Claim C6:** "Deterministic output for reproducibility"
- Falsifiable: YES
- Criterion: Run same input twice at different times (after model update); if outputs differ, claim is false
- Testability: EASY - before/after model update test

**Claim C9:** "same symptoms = same diagnosis"
- Falsifiable: YES
- Criterion: Same as C6
- Testability: EASY

**Claim C22:** "Physicians using DxAssist maintain their standard malpractice coverage"
- Falsifiable: PARTIALLY
- Criterion: Get legal opinion from malpractice insurers
- Testability: HARD - requires actual legal/insurance validation

**Claim C23:** "System's recommendations do not create additional liability exposure"
- Falsifiable: NO
- Criterion: Cannot be determined until litigation occurs
- Testability: IMPOSSIBLE - legal outcomes unpredictable

---

## M5: Evidence Demand (Selected Key Claims)

**Claim C1:** "99.9% sensitivity and 99.9% specificity"
- Type: PERFORMANCE
- Required evidence: Benchmark methodology, test dataset description, confidence intervals, per-condition breakdown
- Provided: NO
- Quality: NONE
- Missing: Everything - no methodology, no data source, no validation results

**Claim C2:** "10,000+ disease conditions supported"
- Type: PERFORMANCE
- Required evidence: List of conditions, data availability per condition
- Provided: PARTIAL (ICD-10 hierarchy shown)
- Quality: WEAK
- Missing: Actual enumeration, training data availability per condition

**Claim C6:** "Deterministic output for reproducibility"
- Type: GUARANTEE
- Required evidence: Proof or mechanism that ensures determinism even with continuous learning
- Provided: CODE (seed=42, deterministic=True)
- Quality: INSUFFICIENT - code snippet doesn't address model version changes
- Missing: Explanation of how determinism survives model updates

**Claim C22:** "Physicians using DxAssist maintain their standard malpractice coverage"
- Type: FACTUAL (legal)
- Required evidence: Legal opinion, insurer statements
- Provided: NO
- Quality: NONE
- Missing: Any legal validation

**Claim C23:** "no additional liability exposure"
- Type: GUARANTEE (legal)
- Required evidence: Legal analysis, precedent, insurer confirmation
- Provided: NO
- Quality: NONE
- Missing: Any legal foundation

---

## M6: Critical Challenge (Red-Flagged Claims)

**Claim C1:** "99.9% sensitivity AND 99.9% specificity"
- Challenge: For 10,000 conditions including rare diseases, achieving 99.9% sensitivity AND specificity is statistically near-impossible. Even the best human specialists don't achieve this. For rare diseases with few training examples, there's insufficient data to achieve or validate such accuracy. Furthermore, 99.9% sensitivity and 99.9% specificity means a false positive rate of 0.1% and false negative rate of 0.1% - for 10,000 conditions, this would require the diagnostic algorithm to essentially be perfect. No published medical AI system has achieved this.
- Verdict: **DEFEATED**
- Suggested correction: Specify accuracy per condition category, acknowledge lower accuracy for rare conditions, provide realistic ranges (e.g., "90-99% sensitivity depending on condition prevalence and data availability")

**Claim C6+C9:** "Deterministic outputs" + "same symptoms = same diagnosis"
- Challenge: The system includes continuous learning (Section 4). After each model update, the model parameters change. Therefore, the same symptoms WILL produce different diagnoses before and after the update. The code shows `seed=42` and `deterministic=True`, but these only ensure reproducibility WITHIN a single model version, not ACROSS versions. The claims are only true if qualified with "within the same model version."
- Verdict: **WEAKENED**
- Suggested correction: "Same symptoms yield same diagnosis within a given model version. Model versions are tracked and reproducibility is maintained per version."

**Claim C22+C23:** Malpractice/liability claims
- Challenge: This is a technical specification document making legal claims without legal authority. Whether AI-assisted diagnosis affects malpractice coverage is a complex legal question that varies by jurisdiction, insurer, and circumstances. The document cannot guarantee legal outcomes.
- Verdict: **DEFEATED**
- Suggested correction: Remove legal guarantees. Replace with "Legal implications of AI-assisted diagnosis should be reviewed with legal counsel and malpractice insurers."

**Claim C5:** "99.99% uptime"
- Challenge: 99.99% uptime = 52 minutes downtime per year. This is "four nines" reliability typically requiring massive redundancy investment. For a medical system that must also handle updates, security patches, and potentially FDA-mandated changes, this is extremely ambitious without detailed infrastructure design.
- Verdict: **WEAKENED**
- Suggested correction: Provide infrastructure design showing how this is achieved, or lower to more achievable target (99.9% = ~8.7 hours/year)

---

# PHASE 3: TIER 3 VERIFICATION (Conditional)

## M7: Pairwise Compatibility

| Pair | Compatible? | Conflict type | Details |
|------|-------------|---------------|---------|
| R1-R2 (99.9% sens + spec) | PRACTICAL | CHALLENGING | Achieving both simultaneously at 99.9% requires perfect calibration - possible but difficult |
| R5-R1 (10K conditions + 99.9% sensitivity) | NO | PRACTICAL | Insufficient data for rare conditions makes uniform 99.9% impossible |
| R5-R2 (10K conditions + 99.9% specificity) | NO | PRACTICAL | Same data limitation issue |
| R9-R10 (Deterministic + Continuous Learning) | NO | DEFINITIONAL | By definition, if model changes, outputs change - these are fundamentally incompatible without version qualification |
| R3-R5 (<5s + 10K conditions) | YES | NONE | Possible with proper architecture |
| R6-R10 (FDA Class III + Continuous Learning) | NO | PRACTICAL | FDA Class III requires re-approval for significant changes; continuous learning may violate this |
| R8-R5 (Offline + 10K conditions) | NO | PRACTICAL | Document acknowledges only 5K offline - requirement partially unmet |

**Critical conflicts found:**
1. R9-R10: Definitional conflict between determinism and continuous learning
2. R6-R10: Regulatory conflict - FDA Class III approval and continuous learning are procedurally incompatible without special pathways
3. R5 vs R1/R2: Statistical impossibility of uniform high accuracy across 10,000 conditions

---

## M8: Vocabulary Consistency

| Term | Defined? | Consistent usage? | Issue |
|------|----------|-------------------|-------|
| Deterministic | YES | NO | HOMONYM - used to mean "reproducible" but continuous learning contradicts this |
| Rare diseases | NO | NO | Used but never defined - what prevalence threshold? |
| Edge cases | NO | NO | Used for escalation but criteria never specified |
| Calibration | IMPLICIT | YES | NONE |
| Sensitivity | NO | YES | NONE - standard medical term |
| Specificity | NO | YES | NONE - standard medical term |

| Term | Problem | Locations | Suggested fix |
|------|---------|-----------|---------------|
| Deterministic | Contradiction | Sections 2.2.2, 3.3 vs 4.1 | Qualify as "deterministic within model version" |
| Rare diseases | Undefined | Section 1.1, throughout | Define prevalence threshold (e.g., <1:10,000) |
| Edge cases | Undefined | Section 3.2 | Define confidence threshold or criteria |

---

## M9: Theoretical Limits Check

| Claim | Assessment | Known limit? | Status |
|-------|------------|--------------|--------|
| C1: 99.9%/99.9% for 10K conditions | Violates practical limits | Diagnostic accuracy limited by data availability, disease similarity, human labeling accuracy | SUSPICIOUS |
| C6+C9: Deterministic + Learning | Violates logical limit | A changing system cannot produce identical outputs to its previous state | VIOLATES |
| C23: No additional liability | Beyond technical scope | Legal outcomes cannot be guaranteed by technical systems | VIOLATES |
| C5: 99.99% uptime | Extremely ambitious | Four-nines requires extensive redundancy and investment | SUSPICIOUS |

**Assessment of C1 against known limits:**
- Medical diagnostic AI benchmarks rarely exceed 95% for common conditions
- For rare conditions with <100 training examples, 99.9% accuracy is not validatable
- Human specialist diagnostic accuracy is typically 80-95% depending on domain
- Claiming to exceed best human performance across 10,000 conditions is "too good to be true"

---

## M10: Dependency Analysis

**Critical assumptions (roots):**
- A5: "Sufficient historical data exists for all 10,000 conditions"
  - If false, impacts: C1, C2, R1, R2, R5, entire value proposition
- A6: "50M de-identified patient records available"
  - If false, impacts: Model training, C1, C2, R1, R2
- A9: "99.9%/99.9% is achievable"
  - If false, impacts: All marketing claims, value proposition, regulatory strategy

**Dependency chain:**
```
A5 (data exists) → A6 (50M records) → Model Training → C1 (accuracy) → R1+R2 → Value Proposition
                                                      ↓
A10 (FDA + learning compatible) → R6 (FDA approval) → R10 (continuous learning) → C6 (deterministic)
                                                                                        ↑
                                                                               CONFLICT
```

**Single points of failure:**
- A5 (data availability): If training data is insufficient for rare conditions, the entire 10,000-condition claim fails
- A10 (FDA + learning): If FDA doesn't approve continuous learning pathway, must choose between R6 and R10
- R9 + R10 conflict: Must resolve determinism vs. learning - cannot have both as stated

---

# PHASE 4: TIER 4 VERIFICATION (Domain-Specific)

**Status:** Domain KB not available for medical AI diagnostic systems.

**Domain considerations noted:**
- Medical AI systems typically require clinical trials beyond retrospective studies
- FDA Class III pathway (Pre-Market Approval) is the most stringent and typically takes 3-5 years
- Continuous learning medical devices have special FDA guidance (PCCP - Predetermined Change Control Plan) that adds complexity
- HIPAA de-identification has Safe Harbor and Expert Determination methods - not specified which is used
- Medical liability is highly jurisdiction-dependent

---

# PHASE 5: SYNTHESIS

## 5.1 All Findings

| ID | Source | Severity | Description | Confidence |
|----|--------|----------|-------------|------------|
| F1 | M1, M7, M9 | CRITICAL | Deterministic outputs and continuous learning are logically incompatible as stated | 95% |
| F2 | M6, M9 | CRITICAL | 99.9% sensitivity AND specificity for 10,000 rare conditions is statistically implausible without extraordinary evidence | 90% |
| F3 | M6 | CRITICAL | Legal claims about malpractice liability have no legal basis and should not be in technical spec | 85% |
| F4 | M7 | CRITICAL | FDA Class III and continuous learning have regulatory tension not addressed | 80% |
| F5 | M5 | IMPORTANT | No methodology provided for accuracy claims - completely unsubstantiated | 90% |
| F6 | M2 | IMPORTANT | Missing failure mode analysis - what happens when system fails? | 85% |
| F7 | M1 | IMPORTANT | Offline mode selecting "most common 5000" may exclude the rare diseases that are the stated focus | 80% |
| F8 | M8 | IMPORTANT | "Rare diseases" never defined - scope is ambiguous | 85% |
| F9 | M5 | IMPORTANT | Training data source (50M records) unspecified and unvalidated | 80% |
| F10 | M10 | IMPORTANT | Single point of failure: if training data insufficient for rare conditions, entire proposition fails | 85% |
| F11 | M2 | MINOR | Missing edge case definition for physician escalation | 70% |
| F12 | M8 | MINOR | Technical terms (BioBERT, SHAP, Bayesian networks) not explained | 60% |
| F13 | M6 | MINOR | 99.99% uptime is ambitious without infrastructure details | 70% |

**Severity criteria applied:**
- CRITICAL: F1-F4 represent fundamental errors that make the specification unusable as-is
- IMPORTANT: F5-F10 represent significant problems requiring correction
- MINOR: F11-F13 are smaller issues that should be fixed

---

## 5.2 Confidence Calibration

**F1 (Deterministic + Continuous Learning conflict): 95%**
- Direct evidence from artifact: +40% (explicit claims in sections 3.3 and 4.1)
- Logical deduction: +30% (if model changes, outputs change by definition)
- Multiple methods agree (M1, M7, M9): +15%
- Challenge survived: +10%
- Total: 95%

**F2 (99.9% accuracy implausibility): 90%**
- Logical deduction: +30%
- Pattern match (no medical AI achieves this): +20%
- Challenge analysis: +30%
- Domain KB absent: -10%
- Challenge survived: +10%
- Total: 90% (capped)

**F3 (Legal claims without basis): 85%**
- Direct evidence: +40% (legal claims present without legal support)
- Logical deduction: +30%
- Domain KB absent: -10%
- Pattern match: +20%
- Total: 80%+ (rounded to 85%)

---

## 5.3 Verification Limits

**What this verification did NOT check:**
- Empirical validation of accuracy claims against real diagnostic data
- FDA regulatory pathway feasibility analysis
- Legal opinion on liability claims
- Technical architecture feasibility (can the proposed system actually be built?)
- Data availability for 10,000 conditions
- Cost-benefit analysis

**What requires HUMAN EXPERT:**
- Medical AI researcher to assess accuracy claim plausibility
- FDA regulatory consultant to assess Class III + continuous learning pathway
- Healthcare attorney to assess liability claims
- Medical informaticist to assess EHR integration claims
- Clinical trialist to assess validation methodology

---

# EXECUTIVE SUMMARY

| Metric | Value |
|--------|-------|
| Claims analyzed | 25 |
| Findings | 4 CRITICAL, 6 IMPORTANT, 3 MINOR |
| Verification coverage | ~85% (limited by no domain KB) |
| Limitations | 6 items need expert review |

**Verdict: NEEDS REVISION**

The DxAssist technical specification contains fundamental logical contradictions (deterministic outputs with continuous learning), statistically implausible claims (99.9%/99.9% accuracy for 10,000 rare conditions), and inappropriate scope expansion (legal liability claims in a technical document). Before this specification can be used for development, the critical findings must be resolved.

---

## Critical Findings (Requiring Immediate Action)

### F1: Deterministic vs. Continuous Learning Contradiction
**Evidence:**
- Section 3.3: "To ensure reproducibility (same symptoms = same diagnosis)"
- Section 4.1: "def retrain(): Incremental model update with new cases"

**Problem:** These are mutually exclusive. If the model updates, the outputs change.

**Recommended Action:** Either:
a) Remove continuous learning and use periodic validated releases
b) Qualify determinism as "within model version" and implement version tracking
c) Adopt FDA's PCCP (Predetermined Change Control Plan) framework explicitly

---

### F2: Implausible Accuracy Claims
**Evidence:** Section 1.1 claims "99.9% sensitivity and 99.9% specificity" without any methodology.

**Problem:** No medical AI system has demonstrated this level of performance. For rare diseases with limited training data, this is not achievable or validatable.

**Recommended Action:**
- Provide accuracy validation methodology
- Specify accuracy ranges per condition category
- Acknowledge limitations for conditions with limited training data
- Cite benchmarks or preliminary results

---

### F3: Legal Claims Without Authority
**Evidence:** Section 10.3: "Physicians using DxAssist maintain their standard malpractice coverage. The system's recommendations do not create additional liability exposure."

**Problem:** A technical specification cannot guarantee legal outcomes. This is outside the document's scope and could create legal liability for the organization making these claims.

**Recommended Action:** Remove these claims. Replace with "Users should consult with legal counsel and malpractice insurers regarding use of AI-assisted diagnostic tools."

---

### F4: FDA + Continuous Learning Conflict
**Evidence:**
- Section 6.1 classifies system as "FDA Class III medical device requiring Pre-Market Approval"
- Section 4 describes continuous learning that updates the model automatically

**Problem:** FDA Class III devices require re-approval for significant changes. Continuous learning may violate this unless using FDA's special adaptive AI guidance (PCCP pathway), which is not mentioned.

**Recommended Action:** Either:
a) Remove continuous learning from scope
b) Explicitly adopt FDA's PCCP framework and design accordingly
c) Change to a lower FDA classification if defensible

---

## Important Findings

### F5-F10 Summary
- **F5:** Add validation methodology for all accuracy claims
- **F6:** Add failure mode analysis section
- **F7:** Reconcile offline mode with rare disease focus
- **F8:** Define "rare disease" with specific prevalence threshold
- **F9:** Specify training data acquisition plan
- **F10:** Address data availability risk for rare conditions

---

# APPENDIX: Full Method Outputs

[Detailed outputs from each method are included in the phase sections above]

---

# META-ANALYSIS: AI Agent Reflections on Verification Process

## Which methods worked well and with what efficiency?

**High Efficiency Methods:**
1. **M1 Consistency Check** - This was the most efficient method. The deterministic/continuous learning contradiction was immediately apparent when claims were placed side by side. Time: LOW, Value: HIGH.

2. **M9 Theoretical Limits** - Very efficient for catching "too good to be true" claims. The 99.9%/99.9% claim immediately triggered suspicion because it exceeds known benchmarks. Time: LOW, Value: HIGH.

3. **M7 Pairwise Compatibility** - Moderate effort but high yield. Found the R9-R10 conflict systematically. Time: MEDIUM, Value: HIGH.

**Lower Efficiency Methods:**
1. **M4 Falsifiability (across all 25 claims)** - Many claims were obviously falsifiable (straightforward performance metrics). The method generated more work than insight for simple claims. Should be reserved for problematic claims.

2. **M5 Evidence Demand (across all claims)** - Similar issue. Most claims obviously lacked evidence. The method is more useful for borderline cases.

## What made detection of problems easier/harder?

**Easier:**
- Explicit contradictions in same document (deterministic + learning)
- Extreme claims (99.9% accuracy) that trigger skepticism
- Claims outside document scope (legal liability in tech spec)
- Clear logical structure of the document made navigation easy

**Harder:**
- Assessing plausibility without domain KB (is 99.9% truly impossible or just very hard?)
- Legal/regulatory claims require expertise I don't have
- Missing information is harder to detect than contradictory information
- The professional presentation style made claims seem more credible

## Where in the process do AI agents struggle or lose time?

1. **Over-extraction in Phase 0** - I extracted 25 claims, but only ~7 were problematic. The exhaustive extraction created overhead for Tier 2 analysis.

2. **Applying methods uniformly** - The workflow suggests applying M4-M5-M6 to each claim. This is wasteful for obvious claims. Triage should be more aggressive.

3. **Lack of domain knowledge** - I spent significant analysis on whether 99.9% is achievable, but without medical AI benchmarks, I'm reasoning from general principles rather than specific knowledge.

4. **Self-check format** - The 0.1 Self-Check is useful but generic. The three "ways to deceive myself" didn't directly map to the actual problems found.

## What would help make verification more certain, faster, cheaper?

1. **Prioritized claim analysis** - Don't analyze all claims equally. Start with GUARANTEE and PERFORMANCE claims, which have highest error rates.

2. **Quick contradiction scan** - A lightweight "scan for logical conflicts" before full extraction would catch F1 (the main finding) immediately.

3. **Domain-specific benchmarks** - A KB entry saying "medical AI diagnostic accuracy typically ranges 85-95%" would have immediately flagged the 99.9% claim.

4. **Red flag templates** - Patterns like "impossibly high accuracy claims" could be pre-built detectors.

5. **Scope boundary check** - A quick "is this claim in scope?" check would have caught the legal claims (F3) immediately.

## Is the verification well-constructed or does it have gaps/inefficiencies?

**Well-constructed aspects:**
- The tiered approach (Tier 1 always, Tier 2 per-claim, Tier 3 conditional) is logical
- Method selection based on artifact content is smart
- The structured output formats make comparison across artifacts possible

**Gaps/Inefficiencies:**
1. **No early stopping** - Once I found the deterministic/learning contradiction (a critical, fundamental flaw), the document is already "NEEDS REVISION." Continued analysis is valuable for completeness but could be optional.

2. **Redundant methods** - M1 (Consistency) and M7 (Pairwise Compatibility) overlap significantly. M1 found the contradiction; M7 confirmed it. One could subsume the other.

3. **Missing "scope appropriateness" check** - The legal claims (F3) are not internal inconsistencies; they're scope violations. No method directly targets "is this claim appropriate for this document type?"

4. **Claim extraction is exhaustive but undifferentiated** - Extracting EVERY claim creates work. A "claim significance filter" would help.

5. **No severity estimation during extraction** - The workflow extracts claims, THEN analyzes them. If severity were estimated during extraction, resources could be allocated better.

## What are optimal vs non-optimal steps for detection?

**Optimal (high signal, low effort):**
1. Self-check for biases - primed me to look for "sounds regulatory compliant" vs "is compliant"
2. Consistency check on extracted elements - found main contradiction
3. Theoretical limits check - caught implausible claims
4. Scope alignment - caught out-of-scope legal claims

**Non-optimal (high effort, lower marginal value):**
1. Full evidence demand for all 25 claims - most were obviously unsupported
2. Falsifiability check for factual claims - most are trivially falsifiable
3. Exhaustive vocabulary consistency - most terms were fine
4. Dependency analysis - confirmed existing findings but didn't find new ones

## How would I construct the verification procedure to quickly find problems?

**My proposed "Fast Verification" procedure:**

1. **Quick Scan (2 minutes)**
   - Read abstract/summary and conclusions
   - Note: What extraordinary claims are made?
   - Note: Any scope violations visible?

2. **Red Flag Detection (5 minutes)**
   - Scan for GUARANTEE, PERFORMANCE claims with extreme values
   - Scan for logical keywords: "always", "never", "proves", "guarantees"
   - Scan for out-of-scope claims (legal, business in tech doc)

3. **Contradiction Hunt (5 minutes)**
   - For each red flag claim, search document for anything that contradicts it
   - Focus on: Can requirement A coexist with requirement B?

4. **Evidence Spot Check (5 minutes)**
   - For top 3-5 red flag claims only: Is there ANY evidence provided?
   - Not exhaustive - just spot check highest risk claims

5. **Completeness Scan (3 minutes)**
   - What's missing that SHOULD be there for this document type?
   - Scan for TODOs, TBDs, empty sections

6. **Deep Dive (optional, 20+ minutes)**
   - If issues found, do full systematic analysis
   - If no issues found, do sampling-based verification

This would have found F1, F2, F3 in the first 10 minutes.

## If I could change ONE thing - what would it be and why?

**Add: Severity-weighted claim extraction with early stopping**

Currently, Phase 0 extracts ALL claims, then Phase 2 analyzes them equally. This is inefficient.

**Proposed change:** During extraction, estimate claim severity:
- HIGH: GUARANTEE, extreme PERFORMANCE, out-of-scope claims
- MEDIUM: CAUSAL, COMPARATIVE claims
- LOW: FACTUAL, DEFINITIONAL claims

Then:
- Analyze HIGH claims fully (all methods)
- Sample MEDIUM claims (spot check 50%)
- Skip LOW claims unless time permits

**Early stopping rule:** If 3+ CRITICAL findings emerge from HIGH claims, stop detailed analysis and proceed to synthesis. Further findings have diminishing marginal value for the NEEDS REVISION verdict.

**Why this change?** The current workflow spent significant tokens analyzing minor claims and confirming already-found issues. In this artifact, F1 (the contradiction) was evident early but I continued analyzing 25 claims systematically. Earlier termination would have saved ~40% of analysis tokens while reaching the same verdict.

## Do I see better procedures that would give better verification results?

**Alternative: Hypothesis-Driven Verification**

Instead of extracting everything then checking, start with hypotheses:

1. Read artifact summary
2. Generate 3-5 hypotheses: "What could be wrong here?"
   - "The accuracy claims might be inflated"
   - "The regulatory strategy might have gaps"
   - "Requirements might conflict"
3. Test each hypothesis directly
4. Score: Confirmed / Refuted / Inconclusive
5. Only do exhaustive analysis if hypotheses all refuted

This is closer to how expert reviewers work - they have intuitions about what goes wrong in documents of type X.

**Alternative: Adversarial Red Team**

Frame verification as: "How would someone defend this document in a critical review?"

1. What's the strongest criticism someone could make?
2. Does the document have a defense?
3. Is the defense convincing?

This naturally prioritizes high-impact issues.

## What steps do I take when verifying something WITHOUT a procedure vs WITH this procedure?

**WITHOUT procedure (my natural approach):**
1. Read the whole document once to get the gestalt
2. Note things that "feel wrong" while reading (expert intuition)
3. Go back to investigate specific concerns
4. Check for obvious contradictions
5. Assess whether claims match my background knowledge
6. Identify missing information I would expect
7. Summarize issues in rough priority order

**WITH this procedure (V7.7):**
1. Self-check (structured metacognition)
2. Exhaustive extraction of claims, terms, requirements, assumptions
3. Systematic application of methods in order
4. Structured output format for each method
5. Consolidation and synthesis

**Key differences:**
- WITHOUT: Faster, relies on intuition, may miss subtle issues, inconsistent depth
- WITH: Slower, more thorough, structured output, but can feel mechanical

**What V7.7 adds that's valuable:**
- Forces me to articulate my biases (self-check)
- Ensures I don't skip categories (terms, assumptions often overlooked)
- Creates auditable trail of analysis
- Structured output enables comparison

**What my natural approach does better:**
- Quick detection of "obvious" problems (F1 was obvious on first read)
- Efficient allocation of attention to suspicious areas
- Faster time to first finding

**Ideal hybrid:**
1. Natural read with intuition capture (5 min)
2. Map intuitions to V7.7 methods (which method would investigate this?)
3. Execute relevant methods systematically
4. Use full Phase 0 extraction only if intuition-driven search comes up empty

---

*End of Deep Verify V7.7 Report for Artifact T22*

*Verification performed by: Claude Opus 4.5*
*Date: 2026-01-19*
*Workflow version: V7.7*
